Therapeutic management of patients with COVID-19: a systematic review

Infection Prevention in Practice

Volumn 2, Issue 3, 2020, Pages

  Tobaiqy, M ^a   Qashqary, M ^a   Al Dahery, S ^a   Mujallad, A ^a   Hershan, A A ^a   Kamal, M A ^a   Helmi, N ^a  

^a UNIVERSITY OF JEDDAH   (Saudi Arabia)

Author keywords

Arbidol hydrochloride; Convalescent plasma therapy; Corticosteroids; COVID 19; Hydroxychloroquine; SARS CoV 2

Indexed keywords

ANTIBIOTIC AGENT; ANTIVIRUS AGENT; ARBIDOL; AZITHROMYCIN; CEPHALOSPORIN DERIVATIVE; CHLOROQUINE; COBICISTAT PLUS DARUNAVIR; CORTICOSTEROID; DEXAMETHASONE; FAVIPIRAVIR; GANCICLOVIR; GLUCOCORTICOID; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; LINEZOLID; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; METHYLPREDNISOLONE; MOXIFLOXACIN; OFLOXACIN; OSELTAMIVIR; PERAMIVIR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RECOMBINANT ALPHA2B INTERFERON; REMDESIVIR; RIBAVIRIN; THALIDOMIDE; THYMOSIN; TIGECYCLINE; UNINDEXED DRUG;

CHINA; CLINICAL PRACTICE; CONVALESCENCE; CORONAVIRUS DISEASE 2019; DRUG USE; EGYPT; EUROPE; HUMAN; PLASMAPHERESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SAUDI ARABIA; SCIENTIFIC LITERATURE; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; SYSTEMATIC REVIEW; UNITED STATES;

EID: 85115906233     PISSN: None     EISSN: 25900889     Source Type: Journal    
DOI: 10.1016/j.infpip.2020.100061     Document Type: Review

References (65)

1. Yang, W., Cao, Q., Qin, L., Wang, X., Cheng, Z., Pan, A., et al. Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): a multi-center study in Wenzhou city, Zhejiang, China. [published online ahead of print, 2020 Feb 26] J Infect S0163–4453:20 (2020), 388–393, 10.1016/j.jinf.2020.02.016.
2. Guan, W., Ni, Z., Hu, Y., Liang, W., Ou, C., He, J., et al. Clinical characteristics of coronavirusdisease 2019 in China. N Engl J Med 382 (2020), 1708–1720, 10.1056/NEJMoa2002032.
3. Dong, L., Hu, S., Gao, J., Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther 14 (2020), 58–60.
4. Gurwitz, D., Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res, 2020, 1–4, 10.1002/ddr.21656.
5. Chen, C., Qi, F., Shi, K., Li, Y., Li, J., Chen, Y., et al. Thalidomide combined with low-dose glucocorticoid in the treatment of COVID-19 pneumonia. Preprints, 2020, 2020020395 https://www.preprints.org/manuscript/202002.0395/v1.
6. Colson, P., Rolain, J.M., Raoult, D., Chloroquine for the 2019 novel coronavirus SARS-CoV-2. Int J Antimicrob Agents, 2020, 105923, 10.1016/j.ijantimicag.2020.105923.
7. Colson, P., Rolain, J.-M., Lagier, J.-C., Brouqui, P., Raoult, D., Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents 55:4 (2020), 1–3, 10.1016/j.ijantimicag.2020.105932.
8. Massachusetts General Hospital. COVID-19 treatment guidance. 2020, MGH, Boston Available at: https://www.massgeneral.org/news/coronavirus/treatment-guidance [last accessed 17 march 2020].
9. Egypt Ministry of Health and Population. Diagnosis and treatment protocol for COVID 19. 2020, Egypt Ministry of Health and Population, Cairo Available at: https://madamasr.com/en/2020/03/19/feature/politics/your-guide-to-coronavirus-in-egypt/ [last accessed March 2020].
10. Saudi Arabia Ministry of Health. Coronavirus disease 19 (COVID-19) guidelines. 2020, Saudi Arabia Ministry of Health, Riyadh Available at: https://www.moh.gov.sa/en/HealthAwareness/EducationalContent/PublicHealth/Pages/corona.aspx [last accessed March 2020].
11. Health Protection Surveillance Centre, Treatment guidelines for COVID-19 in Ireland. 2020, HPSC, Dublin Available at: https://www.hpsc.ie/a-z/respiratory/coronavirus/novelcoronavirus/casesinireland/epidemiologyofcovid-19inireland/ [last accessed March 2020].
12. Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., et al. A trial of lopinavireritonavir inadults hospitalized with severe COVID-19. N Engl J Med 382 (2020), 1787–1799 https://www.nejm.org/doi/full/10.1056/NEJMoa2001282.
13. Cao, J., Hu, X., Cheng, W., Yu, L., Tu, W., Liu, Q., Clinical features and short-term outcomes of 18 patients with corona virus disease 2019 in intensive care unit. Intensive Care Med(46), 2020, 851–853 https:// doi.org/10.1007/s00134-020-05987-7.
14. Chen, C., Zhang, Y., Huang, J., Yin, P., Cheng, Z., Wu, J., et al. Favipiravir versus arbidol for COVID-19: a randomized clinical trial. medRxiv, 2020, 10.1101/2020.03.17.20037432.
15. Chen, J., Hu, C., Chen, L., Tang, L., Zhu, Y., Xu, X., et al. Clinical study of mesenchymal stem cell treating acute respiratory distress syndrome induced by epidemic influenza A (H7N9) infection, a hint for COVID-19 treatment. Engineering, 2020, 10.1016/j.eng.2020.02.006.
16. Chen, J., Fan, H., Zhang, L., Hunag, B., Zhu, M., Zhou, Y., et al. Retrospective analysis of clinical features in 101 death cases with COVID-19. medRxiv, 2020, 10.1101/2020.03.09.20033068.
17. Chen, J., Qi, T., Liu, L., Ling, Y., Qian, Z., Li, T., et al. Clinical progression of patients with COVID-19 in Shanghai, China. J Infect 80-:5 (2020), e1–e6, 10.1016/j.jinf.2020.03.004.
18. Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395 (2020), 507–513, 10.1016/S0140-6736(20)30211-7.
19. Chen, X., Zheng, F., Qing, Y., Ding, S., Yang, D., Lei, C., et al. Epidemiological and clinical features of 291 cases with coronavirus disease 2019 in areas adjacent to Hubei, China: a double-center observational study. medRxiv, 2020, 10.1101/2020.03.03.20030353.
20. Cui, Y., Tian, M., Huang, D., Wang, X., Huang, Y., Fan, L., et al. A 55-day-old female infant infected with COVID 19: presenting with pneumonia, liver injury, and heart damage. J Infect Dis 221:11 (2020), 1775–1781, 10.1093/infdis/jiaa113.
21. Du, Y., Tu, L., Zhu, P., Mu, M., Wang, R., Yang, P., et al. Clinical features of 85 fatal cases of COVID-19 from Wuhan: a retrospective observational study. Am J Respir Crit Care Med, 2020, 10.1164/rccm.202003-0543OC.
22. Gautret, P., Lagier, J., Parola, P., Hoang, V., Meddeb, L., Mailhe, M., et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label nonrandomized clinical trial. Int J Antimicrob Agents, 2020, 105949, 10.1016/j.ijantimicag.2020.105949.
23. Holshue, M.L., DeBolt, C., Lindquist, S., Lofy, K., Wiesman, J., Bruce, H., et al. First case of 2019 novel coronavirus in the United States. N Engl J Med 382 (2020), 929–936, 10.1056/NEJMoa2001191.
24. Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395 (2020), 497–506, 10.1016/S0140-6736(20)30183-5.
25. Huang, M., Yang, Y., Shang, F., Zheng, Y., Zhao, W., Luo, L., et al. Early and critical care in severe patients with COVID-19 in Jiangsu Province, China: a descriptive study. Res Square, 2020, 10.21203/rs.3.rs-17397/v1.
26. Huang, Y., Zhou, H., Yang, R., Xu, Y., Feng, X., Gong, P., Clinical characteristics of 36 non-survivors with COVID-19 in Wuhan, China. medRxiv, 2020, 10.1101/2020.02.27.20029009.
27. Jian-ya, G., Clinical characteristics of 51 patients discharged from hospital with COVID-19 in Chongqing, China. medRxiv, 2020, 10.1101/2020.02.20.20025536.
28. Liang, B., Zhao, Y., Zhang, X., Lu, J., Gu, N., Clinical characteristics of 457 cases with coronavirus disease 2019. 2020, 10.2139/ssrn.3543581 Available at: SSRN.
29. Liao, J., Fan, S., Chen, J., Wu, J., Xu, S., Guo, Y., et al. Epidemiological and clinical characteristics of COVID-19 in adolescents and young adults. medRxiv, 2020, 10.1101/2020.03.10.20032136.
30. Lim, J., Jeon, S., Shin, H., Kim, M., Seong, Y., Lee, W., et al. Case of the index patient who caused tertiary transmission of coronavirus disease 2019 in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 pneumonia monitored by quantitative RT-PCR. J Korean Med Sci, 35(6), 2020, 10.3346/jkms.2020.35.e79.
31. Liu, F., Xu, A., Zhang, Y., Xuan, W., Yan, T., Pan, K., et al. Patients of COVID-19 may benefit from sustained lopinavir-combined regimen and the increase of eosinophil may predict the outcome of COVID-19 progression. Int J Infect Dis 95 (2020), 183–191, 10.1016/j.ijid.2020.03.013.
32. Liu, J., Ouyang, L., Guo, P., Wu, H., Fu, P., Chen, Y., et al. Epidemiological, clinical characteristics and outcome of medical staff infected with COVID-19 in Wuhan, China: a retrospective case series analysis. medRxiv, 2020, 10.1101/2020.03.09.20033118.
33. Liu, W., Zhang, Q., Chen, J., Xiang, R., Song, H., Shu, S., et al. Detection of COVID-19 in children in early January 2020 in Wuhan, China. N Engl J Med 382 (2020), 1370–1371, 10.1056/NEJMc2003717.
34. Liu, Y., Sun, W., Li, J., Chen, L., Wang, Y., Zhang, L., et al. Clinical features and progression of acute respiratory distress syndrome in coronavirus disease 2019. medRxiv, 2020, 10.1101/2020.02.17.20024166.
35. Lo, I.L., Lio, C.F., Cheong, H.H., Lei, C.I., Cheong, T., Zhong, X., et al. Evaluation of SARS-CoV-2 RNA shedding in clinical specimens and clinical characteristics of 10 patients with COVID-19 in Macau. Int J Biol Sci 16 (2020), 1698–1707 https://doi.org/10.7150/ijbs.45357.
36. Mo, P., Xing, Y., Xiao, Y., Deno, L., Zhao, Q., Wang, H., et al. Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. Clin Infect Dis, 2020, 10.1093/cid/ciaa270.
37. Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 323:11 (2020), 1061–1069, 10.1001/jama.2020.1585.
38. Wang, Z., Yang, B., Li, Q., Wen, L., Zhang, R., Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China. Clin Infect Dis, 2020, 10.1093/cid/ciaa272.
39. Wu, C., Hu, X., Song, J., Du, C., Xu, J., Yang, D., et al. Heart injury signs are associated with higher and earlier mortality in coronavirus disease 2019 (COVID-19). medRxiv, 2020, 10.1101/2020.02.26.20028589.
40. Wu, F., Zhao, S., Yu, B., Chen, Y., Wang, W., Song, Z., et al. A new coronavirus associated with human respiratory disease in China. Nature 579 (2020), 265–269 https://www.nature.com/articles/s41586-020-2008-3.
41. Xu, Y., Li, Y., Zeng, Q., Lu, Z., Li, Y., Wu, W., et al. Clinical characteristics of SARS-CoV-2 pneumonia compared to controls in Chinese Han population. medRxiv, 2020, 10.1101/2020.03.08.20031658.
42. Xu, X.W., Wu, X.X., Jiang, X.G., Xu, K.J., Ying, L.J., Ma, C.L., et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-CoV-2) outside of Wuhan, China: retrospective case series. BMJ, 368, 2020, m606, 10.1136/bmj.m606.
43. Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C., et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 8 (2020), 420–422, 10.1016/S2213-2600(20)30076-X.
44. Yang, X., Yu, Y., Xu, J., Shu, H., Xia, J., Liu, H., et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 8 (2020), 475–481, 10.1016/S2213-2600(20)30079-5.
45. Young, B.E., Ong, S.W.X., Kalimuddin, S., Low, J.G., Tan, S.Y., Loh, J., et al. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. JAMA 323:15 (2020), 1488–1494, 10.1001/jama.2020.3204.
46. Zhang, B., Zhou, X., Qiu, Y., Feng, F., Feng, J., Jia, Y., et al. Clinical characteristics of 82 death cases with COVID-19. medRxiv, 2020, 10.1101/2020.02.26.20028191.
47. Zhang, G., Hu, C., Luo, L., Fang, F., Chen, Y., Li, J., et al. Clinical features and outcomes of 221patients with COVID-19 in Wuhan, China. medRxiv, 2020, 10.1101/2020.03.02.20030452.
48. Zhang, J.C., Zhang, X., Wu, G., Yi, J., The potential role of IL-6 in monitoring coronavirus disease 2019. medRxiv, 2020, 10.1101/2020.03.01.20029769.
49. Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., et al. Clinical course and risk factors formortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395 (2020), 1054–1062, 10.1016/S0140-6736(20)30566-3.
50. Russell, C.D., Millar, J.E., Baillie, J.K., Clinical evidence does not support corticosteroid treatment for 2019-CoV lung injury. Lancet 395 (2020), 473–475.
51. Lamontagne, F., Rochwerg, B., Lytvyn, L., Guyatt, H.G., Moller, M.H., Annane, D., et al. Corticosteroid therapy for sepsis: a clinical practice guideline. BMJ, 362, 2018, k3284, 10.1136/bmj.k3284.
52. Chen, J., Ling, Y., Xi, X., Liu, P., Li, F., Li, T., et al. Efficacies of lopinavir/ritonavir and abidol in the treatment of novel coronavirus pneumonia. Chin J Infect Dis, E008, 2020 https://clinicaltrials.gov/ct2/show/NCT04252885.
53. Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., etal, Atrial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. N Engl J Med 382 (2020), 1787–1799 https://www.nejm.org/doi/10.1056/NEJMoa2001282.
54. Sheahan, T.P., Sims, A.C., Leist, S.R., Schäfer, A., Won, J., Brown, A.J., et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun, 11, 2020, 222.
55. Welliver, R., Monto, A.S., Carewicz, O., Schatteman, E., Hassman, M., Hedrick, J., et al. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA 285:6 (2001), 748–754, 10.1001/jama.285.6.748.
56. World Health Organization, Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. Interim guidance. 2020 Mar 13, 2020, WHO, Geneva Available at: https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected [last accessed April 2020].
57. Yao, X., Ye, F., Zhang, M., Cui, C., Huang, B., Niu, P., et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis, 2020, 10.1093/cid/ciaa237.
58. Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 30 (2020), 269–271, 10.1038/s41422-020-0282-0.
59. Vincent, M.J., Bergeron, E., Benjannet, S., Erickson, B.R., Rollin, P.E., Ksiazek, T.G., et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J, 2, 2005, 69.
60. Woodyatt, A., Hollingsworth, J., Westcott, B., Renton, A., Wagner, M., Hayes, M., March 30 coronavirus news. CNN 30 March 2020. Available at: https://edition.cnn.com/world/live-news/coronavirus-outbreak-03-30-20-intl-hnk/h_7a11b7b7563b288686587c03a6e28e88 [last accessed April 2020].
61. Mair-Jenkins, J., Saavedra-Campos, M., Baillie, J.K., Cleary, P., Khaw, F.-M., Lim, W.S., et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis 211 (2015), 80–90.
62. Arabi, Y., Balkhy, H., Hajeer, A.H., Bouchama, A., Hayden, F.G., Al-Omari, A., et al. Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol. Springer Plus, 4, 2015, 709, 10.1186/s40064-015-1490-9.
63. Hung, I.F., To, K.K., Lee, C.-K., Lee, K.-L., Chan, K., Yan, W.-W., et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis 52 (2011), 447–456.
64. de Wilde, A.H., Jochmans, D., Posthuma, C.C., Zevenhoven-Dobbe, J.C., van Nieuwkoop, S., Bestebroer, T.M., et al. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother 58 (2014), 4875–4884.
65. US Food and Drug Administration, Recommendations for investigational COVID-19 convalescent plasma. 2020, FDA, White Oak, MD Available at: https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/investigational-covid-19-convalescent-plasma-emergency-inds [last accessed April 2020].